



Molecular characterization of the human COQ5 C-methyltransferase in coenzyme Q₁₀ biosynthesis[☆]



Theresa P.T. Nguyen^{a,b,1}, Alberto Casarin^{c,1}, Maria Andrea Desbats^c, Mara Doimo^c, Eva Trevisson^c, Carlos Santos-Ocaña^d, Placido Navas^d, Catherine F. Clarke^{a,b,*}, Leonardo Salvati^{c,**}

^a Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095-1569, USA

^b Molecular Biology Institute, University of California, Los Angeles, CA 90095-1569, USA

^c Clinical Genetics Unit, Dept. of Pediatrics, University of Padova, Via Giustiniani 3, Padova 35128, Italy

^d Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC, CIBERER, Instituto de Salud Carlos III, Sevilla, Spain

ARTICLE INFO

Article history:

Received 3 July 2014

Received in revised form 9 August 2014

Accepted 12 August 2014

Available online 23 August 2014

Keywords:

Human COQ gene

Mitochondrial metabolism

Protein complex

Q-biosynthetic intermediate

Saccharomyces cerevisiae

Ubiquinone

ABSTRACT

Coq5 catalyzes the only C-methylation involved in the biosynthesis of coenzyme Q (Q or ubiquinone) in humans and yeast *Saccharomyces cerevisiae*. As one of eleven polypeptides required for Q production in yeast, Coq5 has also been shown to assemble with the multi-subunit complex termed the CoQ-synthome. In humans, mutations in several COQ genes cause primary Q deficiency, and a decrease in Q biosynthesis is associated with mitochondrial, cardiovascular, kidney and neurodegenerative diseases. In this study, we characterize the human COQ5 polypeptide and examine its complementation of yeast *coq5* point and null mutants. We show that human COQ5 RNA is expressed in all tissues and that the COQ5 polypeptide is associated with the mitochondrial inner membrane on the matrix side. Previous work in yeast has shown that point mutations within or adjacent to conserved COQ5 methyltransferase motifs result in a loss of Coq5 function but not Coq5 steady state levels. Here, we show that stabilization of the CoQ-synthome within *coq5* point mutants or by over-expression of COQ8 in *coq5* null mutants permits the human COQ5 homolog to partially restore *coq5* mutant growth on respiratory media and Q₆ content. Immunoblotting against the human COQ5 polypeptide in isolated yeast mitochondria shows that the human Coq5 polypeptide migrates in two-dimensional blue-native/SDS-PAGE at the same high molecular mass as other yeast Coq proteins. The results presented suggest that human and *Escherichia coli* Coq5 homologs expressed in yeast retain C-methyltransferase activity but are capable of rescuing the *coq5* yeast mutants only when the CoQ-synthome is assembled.

© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

Abbreviations: 2D-BN-SDS/PAGE, two-dimensional blue-native-sodium dodecyl sulfate/polyacrylamide gel electrophoresis; DDMQ, demethyl-demethoxy-Q; DDMQH₂, demethyl-demethoxy-QH₂; DMQ, demethoxy-Q; DOD, drop-out growth medium with dextrose; 4HB, 4-hydroxybenzoic acid; HPLC, high performance liquid chromatography; IDMQ, 4-imino-demethoxy-Q; MRM, multiple reaction monitoring; MTase, methyltransferase; pABA, para-aminobenzoic acid; PK, proteinase K; Q, coenzyme Q or ubiquinone; QH₂, coenzyme QH₂, ubiquinol, or ubiquinolone; SD, minimal synthetic media with dextrose; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TCA, trichloroacetic acid; YPD, rich growth medium with dextrose; YPG, rich growth medium with glycerol; YPGal, rich growth medium with galactose

[☆] This work was supported in part by grants from Telthon Italy (GGP13222), the University of Padova (CPDA123573/12), and Fondazione CARIPARO (to L.S.); the Italian Ministry of Health (GR-2009-1578914) (to E.T.); and the National Science Foundation Grant MCB-1330803 (to C.F.C.); and by the National Institutes of HealthS10RR024605 from the National Center for Research Resources for the purchase of the LC-MS/MS system.

* Correspondence to: C. F. Clarke, UCLA Department of Chemistry and Biochemistry, 607 Charles E Young, Drive E, Box 156905, Los Angeles, CA 90095-1569, USA. Tel.: +1 310 825 0771; fax: +1 310 206 5213.

** Correspondence to: L. Salvati, Clinical Genetics Unit, Dept. of Pediatrics, University of Padova, Via Giustiniani 3, Padova 35128, Italy. Tel.: +39 0498211402; fax: +39 0498217619.

E-mail addresses: cathy@chem.ucla.edu (C.F. Clarke), leonardo.salvati@unipd.it (L. Salvati).

¹ Co-first authors.

1. Introduction

Coenzyme Q (ubiquinone or Q) is an essential lipophilic electron carrier found within the mitochondrial inner membrane of eukaryotes and the plasma membrane of many prokaryotes. Q is composed of a polyisoprenoid “tail” that anchors it to the lipid membrane, and a benzoquinone “head” that confers the abilities to shuttle electrons from Complexes I and II to Complex III [1,2]. Q also acts as a cofactor of uncoupling proteins and several mitochondrial dehydrogenases, and in its reduced or hydroquinone form can quench lipid radical species as an antioxidant [3,4].

The biosynthesis of the isoprenoid tail derives from either the mevalonate or 1-deoxy-D-xylulose-5-phosphate pathways [5], with the number of isoprene units varying in different species: six in *Saccharomyces cerevisiae*, eight in *Escherichia coli*, and ten in humans. In *S. cerevisiae*, the hexaprenyl diphosphate tail is attached to either 4-hydroxybenzoic acid (4HB) or para-aminobenzoic acid (pABA), both of which have been shown to serve as aromatic ring precursors in *S. cerevisiae* Q₆ biosynthesis [6,7].

Eleven *S. cerevisiae* genes (*COQ1-9*, *ARH1*, *YAH1*) are required for Q₆ biosynthesis, several of which encode proteins associated with the mitochondrial inner membrane in a multi-subunit complex termed the CoQ-synthome [8]. In the absence or deficiency of any one of these genes, Q₆ is not made and growth on medium containing a non-fermentable carbon source is not possible; the presence of each Coq polypeptide is essential for the assembly of the Coq polypeptide complex and for the proper function of each individual enzyme [9]. The over-expression of *COQ8*, which encodes a putative regulatory kinase, has been shown to restore steady state levels of several Coq polypeptides [10] and the assembly of the high molecular mass CoQ-synthome [8].

In humans, decreased levels of Q₁₀ are associated with mitochondrial, cardiovascular, kidney and neurodegenerative diseases [3,11]. Mutations in *COQ* genes cause primary Q₁₀ deficiency (OMIM #607426), one of the few treatable mitochondrial disorders; in fact some affected patients respond well to oral Q₁₀ supplementation [12]. *COQ* genes are highly conserved throughout evolution, and several human *COQ* genes have complemented the corresponding yeast *coq* null mutant [11,13]. Previously, we have shown that expression of human ADCK3 (a yeast *Coq8* ortholog) fused with an N-terminal yeast mitochondrial leader sequence rescued the growth of yeast *coq8* null mutants and restored de novo Q biosynthesis [14].

In this study, we report the cloning and functional characterization of the human ortholog of yeast *COQ5* and test its ability to complement yeast *coq5* point and null mutants. *Coq5* catalyzes the only C-methylation involved in the synthesis of Q₆ in yeast [15]. Previous work in yeast has shown that certain point mutations within or adjacent to conserved *COQ5* methyltransferase motifs result in a loss of *Coq5* methyltransferase function, but mutants harboring these alleles (*coq5-2*, *coq5-5*) still retain steady state levels of *Coq5* protein [15,16]. Complementation of these yeast point mutants with *ubiE*, an *E. coli* *COQ5* homolog, restored respiration and C-methyltransferase activity [16]. Here, we examine the function of human *COQ5*, and show that expression of human *COQ5* in yeast mutants identifies the functional conservation of the yeast and human Q biosynthetic pathways, with implications for the diagnosis and treatment of Q₁₀ deficiencies in patients.

2. Material and methods

2.1. Yeast strains and growth media

S. cerevisiae strains used in this study are listed in Table 1. Media were prepared as described [17], and included: YPD (2% glucose, 1% yeast extract, 2% peptone), YPGal (2% galactose, 1% yeast extract, 2% peptone, 0.1% glucose), and YPG (3% glycerol, 1% yeast extract, 2% peptone). Synthetic dextrose/minimal medium (SD, SD-Ura, and SD-Ura-Leu) consisted of 0.18% yeast nitrogen base without amino acids, 2% dextrose, 0.14% NaH₂PO₄, and 0.5% (NH₄)₂SO₄, and amino acids (minus uracil or leucine for selective media) were added at final concentrations as described in [15]. Drop-out media with dextrose (DOD) lacking folate and para-amino benzoic acid and with proper amino acid selection were prepared as described in [18]. Plate media contained 2% bacto agar.

Table 1
Genotype and source of yeast strains.

Strain	Genotype	Source or reference
W303-1A	MAT <i>a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1</i>	R. Rothstein ^a
W303Δ <i>COQ5</i>	MAT <i>a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 coq5::HIS3</i>	[15]
CH83-B3	MAT <i>α ade2-1 coq5-2 his3-1,15 ura3-1</i>	[16]
CH316-6B	MAT <i>α coq5-5 trp1-1 ura3-1</i>	[16]

^a Dr. Rodney Rothstein, Department of Human Genetics, Columbia University.

2.2. Identification of human *COQ5*

The human *COQ5* gene (*hCOQ5*) cDNA sequence was identified by screening the Expressed Sequence Tag (EST) database with the tBLASTn algorithm (www.ncbi.nlm.nih.gov/blast) and the yeast protein sequence as bait [19].

2.3. Plasmid construction

Plasmids used in this study are listed in Table 2. Human *COQ5* was amplified from cDNA obtained from human skin fibroblasts [20] using primers *COQ5F* and *COQ5-1077R*. PCR products were cloned in pCRII TOPO (Invitrogen), and the high copy pYES2.1V5His yeast expression vectors (Invitrogen). The *COQ5* insert from pCRIITOP-*COQ5* was then cloned into the centromeric pCM189 vector (EUROSCARF) [21]. Yeast *COQ5* (*yCOQ5*) was amplified from genomic DNA obtained from a wild-type BY4741 strain using standard protocols and cloned into the same vectors. Amplification primers and conditions for all reactions are shown in Table S1. The hybrid yeast-human *COQ5* (*yhCOQ5*) gene was obtained by amplifying a 5' segment of *yCOQ5*, corresponding to the mitochondrial targeting region (encoding aa 1–54; with primers *yCOQ5F* and *hybridCOQ5R*) and the 3' of human *COQ5* (encoding aa 56–327; with primers *hybridCOQ5F* and *COQ5-1037R*). The two PCR products were joined with a sequential PCR protocol [22].

To generate the *COQ5-GFP* fusion gene, the human *COQ5* coding region (devoid of the termination codon) was amplified from pCRIITOP-*COQ5* with primers containing HindIII and PstI restriction sites, digested with HindIII and PstI, and cloned into the pEGFP-N1 vector (Clontech) digested with the same enzymes. Finally a myc-tag was added to the C-terminus of *hCOQ5* by PCR with primers *COQ5F* and *COQ5mycR* (Table S1) and cloned into the pCDNA3.1V5HisTOPO vector (Invitrogen) to yield p*COQ5-myc*. All plasmid-constructs were sequenced to confirm the presence of the inserted DNA segments and to ascertain they were free of errors.

2.4. Northern blot and RACE

The probe for Northern blot analysis was obtained by EcoRI digestion of pCRII TOPO-*COQ5* and was labeled and purified as described in [19] and hybridized to a commercial membrane (FirstChoice Human Blot 1 membrane–Ambion) containing 2 μg/lane of poly(A) + RNA from ten human tissues, previously used as described [23] and stripped. Radioactivity was detected with a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA) after an overnight exposure. The 5' and 3' termini of *COQ5* transcripts were characterized by RACE (Rapid Amplification of cDNA Ends), a protocol that has been detailed elsewhere [19]. RNA was extracted from cultured skin fibroblasts and from HeLa cells. Primers are reported in Table S1.

2.5. Localization of human *COQ5* polypeptide in HeLa and HEK cells

The *COQ5-GFP* construct was used to transfect HeLa cells stably expressing mitochondrial Red Florescent Protein (mtRFP) as previously reported [20]. Procedures for mitochondrial isolation, proteinase K protection assays, and carbonate extraction were performed as described [24]. Antibodies used are described in Table 3. Tagged versions of *COQ5* were employed since our anti-*COQ5* antibody detected only very faint signals in cultured cells.

2.6. Immunoprecipitation of *hCOQ5* from cultured cells

HEK 293 cells were co-transfected with the p*COQ5-myc* and p*COQ4-V5*, and were harvested after 48 h and mitochondria were isolated as above. About 3–4 mg of mitochondria were resuspended in 1 ml of lysis buffer (150 mM NaCl; 10 mM Tris/HCl pH 7.4; 1 mM EDTA; 0.5% Triton X-100; protease and phosphatase inhibitors) and incubated

Download English Version:

<https://daneshyari.com/en/article/8302185>

Download Persian Version:

<https://daneshyari.com/article/8302185>

[Daneshyari.com](https://daneshyari.com)